



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/507,385

09/09/2004

Teizo Yoshimura

4239-64104-02

8908

36218 7590 10/28/2009
KLARQUIST SPARKMAN, LLP
121 S.W. SALMON STREET
SUITE #1600
PORTLAND, OR 97204-2988

EXAMINER

LEAVITT, MARIA GOMEZ

ART UNIT

PAPER NUMBER

1633

MAIL DATE

DELIVERY MODE

10/28/2009

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Advisory Action Before the Filing of an Appeal Brief	Application No. 10/507,385	Applicant(s) YOSHIMURA, TEIZO	
	Examiner MARIA LEAVITT	Art Unit 1633	

--The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

THE REPLY FILED 19 October 2009 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE.

1. ☒ The reply was filed after a final rejection, but prior to or on the same day as filing a Notice of Appeal. To avoid abandonment of this application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or other evidence, which places the application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 37 CFR 41.31; or (3) a Request for Continued Examination (RCE) in compliance with 37 CFR 1.114. The reply must be filed within one of the following time periods:

- a) ☒ The period for reply expires 4 months from the mailing date of the final rejection.
 b) ☐ The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection.

Examiner Note: If box 1 is checked, check either box (a) or (b). ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).

Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

NOTICE OF APPEAL

2. ☐ The Notice of Appeal was filed on _____. A brief in compliance with 37 CFR 41.37 must be filed within two months of the date of filing the Notice of Appeal (37 CFR 41.37(a)), or any extension thereof (37 CFR 41.37(e)), to avoid dismissal of the appeal. Since a Notice of Appeal has been filed, any reply must be filed within the time period set forth in 37 CFR 41.37(a).

AMENDMENTS

3. ☒ The proposed amendment(s) filed after a final rejection, but prior to the date of filing a brief, will not be entered because
 (a) ☒ They raise new issues that would require further consideration and/or search (see NOTE below);
 (b) ☐ They raise the issue of new matter (see NOTE below);
 (c) ☐ They are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or
 (d) ☐ They present additional claims without canceling a corresponding number of finally rejected claims.

NOTE: See Continuation Sheet. (See 37 CFR 1.116 and 41.33(a)).

4. ☐ The amendments are not in compliance with 37 CFR 1.121. See attached Notice of Non-Compliant Amendment (PTOL-324).
 5. ☐ Applicant's reply has overcome the following rejection(s): _____.
 6. ☐ Newly proposed or amended claim(s) _____ would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).
 7. ☒ For purposes of appeal, the proposed amendment(s): a) ☒ will not be entered, or b) ☐ will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended.
 The status of the claim(s) is (or will be) as follows:
 Claim(s) allowed: _____.
 Claim(s) objected to: _____.
 Claim(s) rejected: 11-13, 17-25 and 55-59.
 Claim(s) withdrawn from consideration: 1-9, 15, 16, 26-33 and 46-54.

AFFIDAVIT OR OTHER EVIDENCE

8. ☐ The affidavit or other evidence filed after a final action, but before or on the date of filing a Notice of Appeal will not be entered because applicant failed to provide a showing of good and sufficient reasons why the affidavit or other evidence is necessary and was not earlier presented. See 37 CFR 1.116(e).
 9. ☐ The affidavit or other evidence filed after the date of filing a Notice of Appeal, but prior to the date of filing a brief, will not be entered because the affidavit or other evidence failed to overcome all rejections under appeal and/or appellant fails to provide a showing of good and sufficient reasons why it is necessary and was not earlier presented. See 37 CFR 41.33(d)(1).
 10. ☐ The affidavit or other evidence is entered. An explanation of the status of the claims after entry is below or attached.

REQUEST FOR RECONSIDERATION/OTHER

11. ☒ The request for reconsideration has been considered but does NOT place the application in condition for allowance because:
See Continuation Sheet.
 12. ☐ Note the attached Information *Disclosure Statement*(s). (PTO/SB/08) Paper No(s). _____.
 13. ☐ Other: _____.

/Maria Leavitt/
 Primary Examiner, Art Unit 1633

Continuation of 3. NOTE: Amended claim 19 introduces specific limitations, i.e., "contacting the immature macrophage or the immature dendritic cells with a differentiation agent that enhances macrophage or dendritic cell maturation ", claim 20 introduces specific limitations, i.e., "wherein the differentiation agent comprises tumor necrosis factor-alpha, lipopolysaccharide, or phorbol 12- myristate 13-acetate, or a combination thereof", claim 58 introduces specific limitations, i.e., "contacting the immature macrophage or the immature dendritic cells with a differentiation agent that enhances macrophage or dendritic cell maturation wherein the differentiation agent comprises interleukin-4 or granulocyte-macrophage-colony stimulating factor, or a combination thereof", and claim 59 introduces specific limitations, i.e., "contacting the immature macrophage or the immature dendritic cells with a differentiation agent that enhances macrophage or dendritic cell maturation wherein the differentiation agent that enhances monocyte or dendritic maturation is CD40".

None of the claims previously examined recited "contacting the immature macrophage or the immature dendritic cells with a differentiation agent that enhances macrophage or dendritic cell maturation ", "wherein the differentiation agent comprises tumor necrosis factor-alpha, lipopolysaccharide, or phorbol 12- myristate 13-acetate, or a combination thereof", "contacting the immature macrophage or the immature dendritic cells with a differentiation agent that enhances macrophage or dendritic cell maturation wherein the differentiation agent comprises interleukin-4 or granulocyte-macrophage-colony stimulating factor, or a combination thereof", and "contacting the immature macrophage or the immature dendritic cells with a differentiation agent that enhances macrophage or dendritic cell maturation wherein the differentiation agent that enhances monocyte or dendritic maturation is CD40". These limitations were not previously examined requiring new search and consideration of the art made of record, and of the specification for support of the amendment. In addition, claims 60 has been newly added. This requires new consideration of the prior art of record, which has not been relied upon to teach the effective amounts of active steps (i), (ii) and (iii) inducing maturation of the immune macrophage or the immature dendritic cells that expresses DDR1, and perhaps a new search. Therefore, the amendment to the claims filed on 10-19-2009 has not been entered.

Continuation of 11. does NOT place the application in condition for allowance because: Applicants' arguments rely upon and are directed to the proposed amendments (pages 8 and 9 of Applicants' remarks filed on 10-19-2009). As the claims' amendment has not been entered, applicants' arguments based on the proposed amendment are not persuasive. Therefore, the rejections of record are maintained..